Vancomycin for ulcerative colitis and PSC
Treatments studied
Part of Digestive system clinical trials.
This trial tests if vancomycin, an antibiotic, can reduce inflammation in people with both ulcerative colitis (UC) and primary sclerosing cholangitis (PSC). It aims to see if the drug helps control disease activity in moderate to severe UC.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with both ulcerative colitis and primary sclerosing cholangitis.
- Your UC is moderate to severe, meaning you have symptoms like frequent diarrhea, bleeding, and inflammation seen on a scope.
- You have not used antibiotics or probiotics in the last 4 weeks (for a special stool study).
- You do not have severe liver or kidney problems, active infections, or hearing issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a specific antibiotic called vancomycin can help children with an unusual type of gut inflammation (colitis). The researchers believe an imbalance in gut bacteria may be causing the problem, and vancomycin might restore that balance.
This study tests an investigational medication called LY4268989 for adults with moderate to severe ulcerative colitis (UC). It's for people who have tried other treatments without success. The goal is to see if the drug can reduce inflammation and improve symptoms.
This trial tests an experimental drug called ENC1018 for people with moderate-to-severe ulcerative colitis who haven't responded well to standard treatments. It aims to see if the drug is safe and works well.
This study tests a new drug called XmAb942 for people with moderate to severe ulcerative colitis. It aims to see if the drug can reduce inflammation and improve symptoms when other treatments haven't worked well enough or caused side effects.
This trial tests if a fecal microbiota transplant (FMT) can help people with primary sclerosing cholangitis (PSC) and inactive inflammatory bowel disease (IBD). It compares FMT against a placebo to see if it improves liver health.
This Phase 2 study tests whether the antibiotic vancomycin can improve primary sclerosing cholangitis (PSC), a long-term bile-duct disease. You may be eligible if you have confirmed PSC and certain blood test and safety criteria, and you can follow medication washout rules.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.